SMITHS FALLS, ON, Feb. 10, 2015 /CNW/ - Tweed Marijuana Inc.
(Tweed) and Canabo Medical Corporation (Canabo) are pleased to
announce the launch of a collaborative research partnership on
marijuana for medical purposes.
Canabo will conduct scientific and medical research through its
network of healthcare practitioners at its medical clinics. This
research data will be used to generate data to clarify the role of
cannabis in various chronic conditions, including the management of
chronic pain.
"Research data that is collected will be useful for a range of
stakeholders including other clinicians, policy makers and to all
industry involved in growing, selling, and marketing cannabis as a
therapeutic modality," said Canabo CEO JC St-Amour. "Healthcare
practitioners are seeking more information on how to practically
incorporate cannabis into their practices, and accumulating a
large-scale and reliable clinical dataset on the use of
cannabinoids in clinical practice will be a major step forward in
this endeavor. Partnering with Tweed and their customers on
this research makes sense given their capability to provide a
reliable supply of high quality medicine, and their reputation as a
leader in customer care."
The scientific study will include establishing and implementing
data management protocols and devising a systematic scientific
methodology to capture consistent and complete study data.
Research data will be conducted on real-world datasets, and
patients who are enrolled in the scientific and medical research
program (currently 1,100 patients, and projected to climb to over
15,000 patients) will have their data anonymously collected to be
able to answer a range of research questions. The data is
expected to provide a preliminary indication as to the effect of
various cannabis strains on a range of chronic conditions. It
will also contribute to clarifying specific dosages, modes of
administration, and frequency for various conditions.
"Tweed's focus has been on research and medical education since
the very beginning," said Bruce
Linton, Chairman and Co-founder of Tweed. "We are proud to
be the first partner in this exciting project and hope and expect
to see further Licensed Producers become involved in this important
work over the coming months."
The data acquired through this medical research will ensure that
Tweed and future partners can continue to breed and grow the best
medicine for patients, while building a knowledge base to help
inform the dialogue with doctors about the place for medical
cannabis within their practices.
About Canabo Medical Corporation
Canabo Medical Corporation is at the forefront of patient care
in the field of prescription cannabinoids and medical
marijuana. Its referral-only clinics incorporate
evidence-based medicine in combination with expert opinion to
provide a safe approach to treating the needs of patients suffering
from chronic and disabling illnesses to improve their quality of
life. The staff is dedicated to helping patients find
effective treatment for chronic and serious conditions through the
use of prescription cannabinoids and herbal cannabis, educating
patients, physicians and the community and advancing research in
the field of cannabinoids.
About Tweed
Tweed is Canada's first
publicly traded medical marijuana company and the first
geographically diversified producer with dual licenses under the
Health Canada Marihuana for Medical Purposes
Regulations.
Tweed provides an industry-leading selection of strains to
customers who are seeking to treat their symptoms in a reliable,
consistent way with a deep commitment and focus on customer
care.
Notice regarding Forward Looking Statements
This news release contains forward-looking statements.
Often, but not always, forward-looking statements can be identified
by the use of words such as "plans", "expects" or "does not
expect", "is expected", "estimates", "intends", "anticipates" or
"does not anticipate", or "believes", or variations of such words
and phrases or state that certain actions, events or results "may",
"could", "would", "might" or "will" be taken, occur or be
achieved. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Tweed Marijuana
Inc. or Tweed Inc. to be materially different from any future
results, performance or achievements expressed or implied by the
forward-looking statements. Examples of such statements include:
(A) predictions of future demand; (B) plans to increase capital
expenditure and construction related expenses; (C) anticipated
production yields; (D) completion of construction and availability
of new production rooms; and (E) forecasted available product
selection. Actual results and developments are likely to differ,
and may differ materially, from those expressed or implied by the
forward-looking statements contained in this news release. Such
forward-looking statements are based on a number of assumptions
which may prove to be incorrect, including, but not limited to: the
ability to obtain any necessary financing; the economy generally;
the yield from Tweed's marijuana growing operations; consumer
interest in products; competition; regulation and anticipated and
unanticipated costs and delays. Although Tweed Marijuana Inc. has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results not to be as anticipated,
estimated or intended. Readers should not place undue reliance on
forward-looking statements. The factors identified above are not
intended to represent a complete list of the factors that could
affect Tweed Marijuana Inc. or Tweed Inc. Additional factors are
noted under "Part IV - Description of Risk Factors Associated with
the Acquisition" in the Filing Statement of Tweed Marijuana Inc.
dated as of June 30, 2014 and available at
www.SEDAR.com. The forward-looking statements included in
this news release are made as of the date of this news release and
Tweed Marijuana Inc. does not undertake an obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Tweed Marijuana Inc.